Ability of the rhTSH stimulation test to predict relapse in patients with differentiated thyroid carcinoma, after long-term follow-up

  • Authors:
    • Mafalda Marcelino
    • Ana Filipa Lopes
    • Deolinda Madureira
    • Teresa C. Ferreira
    • Edward Limbert
    • Valeriano Leite
  • View Affiliations

  • Published online on: January 7, 2015     https://doi.org/10.3892/ol.2015.2854
  • Pages: 1281-1286
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The analysis of serum thyroglobulin (Tg) following thyroid‑stimulating hormone (TSH) stimulation (sTg) has been recommended in the follow‑up of differentiated thyroid carcinoma (DTC) patients, however, its routine use remains controversial. The aim of the current study was to evaluate the accuracy of sTg testing following recombinant human (rh) TSH stimulation in DTC patients, with a follow‑up of 12.4 years. Retrospective studies were conducted of 125 DTC patients, who underwent rhTSH stimulation testing between 1999 and 2002. The exclusion criteria were: Patients with anti‑Tg antibodies, Tg levels >1 ng/ml under TSH suppression and the absence of radioactive iodine (RAI) ablation therapy following surgery. In total, 49 patients were included in the study and all had been previously treated with total or near total thyroidectomy (with or without central neck dissection) and RAI, postoperatively. The Tg functional sensitivity was 1.0 ng/ml. The follow‑up for patients was performed annually. During the median follow‑up of 12.4 years after the rhTSH stimulation test, nine patients exhibited recurrence (18.4%). Of the nine patients, six exhibited sTg levels >2 ng/ml (positive result) and three exhibited levels <2 ng/ml (negative result). Relapse occurred at a mean of 5.9 years following the rhTSH stimulation test. The positive predictive value and negative predictive value (NPV) of positive sTg were 50 and 91.9%, respectively, with a sensitivity of 66.6% and a specificity of 85.0%. The rhTSH‑stimulated Tg levels have a high NPV, allowing the identification of the patients who are free of the tumour. These results are consistent with the previously published data; however, to the best of our knowledge, this is the study with the longest follow‑up duration after rhTSH stimulation.
View Figures
View References

Related Articles

Journal Cover

March-2015
Volume 9 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Marcelino M, Lopes AF, Madureira D, Ferreira TC, Limbert E and Leite V: Ability of the rhTSH stimulation test to predict relapse in patients with differentiated thyroid carcinoma, after long-term follow-up. Oncol Lett 9: 1281-1286, 2015
APA
Marcelino, M., Lopes, A.F., Madureira, D., Ferreira, T.C., Limbert, E., & Leite, V. (2015). Ability of the rhTSH stimulation test to predict relapse in patients with differentiated thyroid carcinoma, after long-term follow-up. Oncology Letters, 9, 1281-1286. https://doi.org/10.3892/ol.2015.2854
MLA
Marcelino, M., Lopes, A. F., Madureira, D., Ferreira, T. C., Limbert, E., Leite, V."Ability of the rhTSH stimulation test to predict relapse in patients with differentiated thyroid carcinoma, after long-term follow-up". Oncology Letters 9.3 (2015): 1281-1286.
Chicago
Marcelino, M., Lopes, A. F., Madureira, D., Ferreira, T. C., Limbert, E., Leite, V."Ability of the rhTSH stimulation test to predict relapse in patients with differentiated thyroid carcinoma, after long-term follow-up". Oncology Letters 9, no. 3 (2015): 1281-1286. https://doi.org/10.3892/ol.2015.2854